Max Robotics — Global Service Robot Directory + US Certification

About

David Roberge is a leading radiation oncologist whose research has significantly advanced the application of stereotactic body radiotherapy (SBRT) and robotic radiosurgery, particularly for thoracic and abdominal malignancies. His work is centered on refining high-precision, patient-adapted treatments to improve cancer outcomes while meticulously managing toxicity. A major contribution is his landmark study on robotic lung SBRT, which demonstrated excellent cancer control in early-stage non-small cell lung cancer but issued a critical caution regarding the severe risks for patients with idiopathic pulmonary fibrosis—a finding that has shaped clinical guidelines. His investigations into long-term quality of life after lung SBRT, with 24 citations, provide essential patient-centered data. Roberge has also pioneered techniques for challenging sites, including stereotactic irradiation for choroidal melanoma and SBRT for locally advanced pancreatic cancer, showcasing the versatility of robotic platforms. His work on fiducial implantation for liver SBRT and the characterization of rare toxicities, such as the “fingers of death” phenomenon in liver radiosurgery, underscores his commitment to both technical innovation and patient safety. With over 80 total citations on these key works, Roberge’s research continues to inform safer, more effective stereotactic treatments across multiple disease sites.